SCHEMBL947564

SCHEMBL947564

CN(C)Cc1ncc2n1C(=O)N(C1CCN(Cc3ccccc3)CC1)C2

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 6/20 0.45
CHRM3 P20309 6/20 0.45
DRD2 P14416 7/20 0.42
DRD4 P21917 7/20 0.42
DRD3 P35462 7/20 0.42
RECQL P46063 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
OPRM1 P35372 1/20 0.41
OPRL1 P41146 1/20 0.41
F2 P00734 2/20 0.40
F10 P00742 2/20 0.40
CCR5 P51681 2/20 0.40
ACHE P22303 1/20 0.40
HPN P05981 1/20 0.39
PRSS1 P07477 1/20 0.39
PRSS2 P07478 1/20 0.39
PRSS3 P35030 1/20 0.39
HGFAC Q04756 1/20 0.39
ST14 Q9Y5Y6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL950090 0.89 RECQL (0.45) CHRM2CHRM3DRD2DRD4DRD3
SCHEMBL949180 0.86 F10 (0.49) CHRM2CHRM3DRD2DRD4DRD3
SCHEMBL948780 0.85 ACHE (0.43) CHRM2CHRM3DRD2DRD4DRD3
SCHEMBL949174 0.84 CHRM2 (0.49) CHRM2CHRM3DRD2DRD4DRD3
SCHEMBL948506 0.82 CHRM3 (0.42) CHRM2CHRM3DRD2DRD4DRD3
SCHEMBL949320 0.81 CHRM3 (0.41) CHRM2CHRM3DRD2DRD4DRD3
SCHEMBL947325 0.80 CHRM2 (0.40) CHRM2CHRM3SMN1; SMN2OPRM1OPRL1
SCHEMBL949956 0.79 CHRM3 (0.48) CHRM2CHRM3DRD2DRD4DRD3
SCHEMBL947735 0.73 SMN1; SMN2 (0.48) SMN1; SMN2F2F10
SCHEMBL947720 0.72 CHRM2 (0.50) CHRM2CHRM3DRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009389-A1 IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-01-13 US disclosed
US-20070004736-A1 Imidazole derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-01-04 US disclosed
EP-1564213-A1 IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2005-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004736-A1 Imidazole derivative, process for producing the same, and use HRH4, F2, HRH2 CHRM2 576/4885CHRM3 1166/4885DRD2 77/4885
US-20110009389-A1 IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE F2, H1-3, CYC1 CHRM2 1002/4885CHRM3 1727/4885DRD2 227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.